3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
5
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Rectal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Colonic Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Oxaliplatin
26
Gemcitabine
22
Fluorouracil
17
Capecitabine
16
Leucovorin
15
pembrolizumab
14
Docetaxel
14
Cisplatin
13
Bevacizumab
12
Radiotherapy
8
Paclitaxel
8
Irinotecan
8
Trastuzumab
7
Pemetrexed
6
Carboplatin
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
cemiplimab
5
Erlotinib Hydrochloride
5
Sunitinib
4
Ramucirumab
4
Metformin
4
Gefitinib
4
trastuzumab deruxtecan
3
tislelizumab
3
cabozantinib
3
atezolizumab
3
Taxes
3
Sorafenib
3
Panitumumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma
×
tegafur-gimeracil-oteracil
×
Clear all
NCT05161572
2025-06-18
NeoRacing
Fudan University
Phase 2
Terminated
6 enrolled